Applied Clinical Trials
Survey reveals mixed adoption of paperless data collection in clinical trials, pointing to the need for greater alignment of new eClinical technologies and study conduct.
In January 2014, the FDA presented a webinar “Promoting eSource Data Capture,” to explain its Final Guidance on Electronic Source Data in Clinical Investigations. In a slide, the FDA said the worst case for source data capture is “transcription of data from paper or electronic sources to the eCRF (electronic case report form).” The reason being that there was no intervening paper step needed, less confusion on what is source and the decreased likelihood of data errors.
In April of this year, we conducted a survey with SCORR Marketing to evaluate the paperless trial. In this survey, of 143 respondents, 25% said 0%-10% of their data collection in clinical trials was paperless. The next highest was 22%, who said that greater than 75% of their trials were paperless. And 15% said between 51% and 75% were paperless. So the majority fall in the middle of paperless processes, leaving room for greater adoption in the coming years.
In fact, the majority of respondents-27%-said that in the next three years, 75% to 99% of the processes for clinical trials would be paperless. With the plethora of new technologies surrounding data aggregation, mining, and analytics in all critical areas of study conduct, we can only see that our respondents are correct in their view.
For more information, download SCORR’s free report here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.